• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Response rates high with imiquimod for multiple basal cell

Article

Washington D.C. -- Imiquimod 5 percent cream produces histologic response rates in excess of 70 percent in the treatment of multiple superficial basal cell carcinomas, according to study data presented at the 62nd annual meeting of the American Academy of Dermatology.

Related Videos
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
This series features 1 KOL.
This series features 1 KOL.
4 KOLs are featured on this panel.
4 KOLs are featured on this panel.
Latanya Benjamin, MD, FAAD, FAAP, an expert on vitiligo
Latanya Benjamin, MD, FAAD, FAAP, an expert on vitiligo
Latanya Benjamin, MD, FAAD, FAAP, an expert on vitiligo
Latanya Benjamin, MD, FAAD, FAAP, an expert on vitiligo
© 2024 MJH Life Sciences

All rights reserved.